VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Wide Moat Stocks Home My Collections

Stock Comparison

Alibaba Group Holding Limited vs Novartis AG

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Alibaba Group Holding Limited

9988.HK · The Stock Exchange of Hong Kong Limited

Market cap (USD)$2.8T

Gross margin (TTM)41.2%

Operating margin (TTM)10.9%

Net margin (TTM)12.2%

SectorConsumer

IndustrySpecialty Retail

CountryKY

Data as of2025-12-29

Moat score

56/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Alibaba Group Holding Limited's moat claims, evidence, and risks.

View 9988.HK analysis

Novartis AG

NOVN · SIX Swiss Exchange

Market cap (USD)—

Gross margin (TTM)—

Operating margin (TTM)—

Net margin (TTM)—

SectorHealthcare

Industry—

CountryCH

Data as of2026-01-02

Moat score

65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Novartis AG's moat claims, evidence, and risks.

View NOVN analysis

Comparison highlights

Moat score gap: Novartis AG leads (65 / 100 vs 56 / 100 for Alibaba Group Holding Limited).
Segment focus: Alibaba Group Holding Limited has 7 segments (41% in Taobao and Tmall Group); Novartis AG has 5 segments (29.3% in Oncology).
Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
Moat breadth: Alibaba Group Holding Limited has 6 moat types across 3 domains; Novartis AG has 4 across 3.

Primary market context

Alibaba Group Holding Limited

Taobao and Tmall Group

Market

China online retail marketplaces & merchant services (Taobao, Tmall, 1688)

Geography

China

Customer

Consumers and merchants/brands

Role

Marketplace + advertising/merchant services

Revenue share

41%

Novartis AG

Oncology

Market

Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)

Geography

Global

Customer

Oncologists and hospitals; reimbursed by payers; hospital and specialty pharmacy channels

Role

Originator developer, manufacturer, and marketer of oncology therapies

Revenue share

29.3%

Side-by-side metrics

Alibaba Group Holding Limited

Novartis AG

Ticker / Exchange

9988.HK - The Stock Exchange of Hong Kong Limited

NOVN - SIX Swiss Exchange

Market cap (USD)

$2.8T

n/a

Gross margin (TTM)

41.2%

n/a

Operating margin (TTM)

10.9%

n/a

Net margin (TTM)

12.2%

n/a

Sector

Consumer

Healthcare

Industry

Specialty Retail

n/a

HQ country

Primary segment

Taobao and Tmall Group

Oncology

Market structure

Oligopoly

Market share

n/a

HHI estimate

n/a

Pricing power

Moderate

Strong

Moat score

56 / 100

65 / 100

Moat domains

Network, Supply, Demand

Legal, Supply, Demand

Last update

2025-12-29

2026-01-02

Moat coverage

Shared moat types

Capex Knowhow ScaleBrand Trust

Alibaba Group Holding Limited strengths

Two Sided NetworkEcosystem ComplementsSwitching Costs GeneralSupply Chain Control

Novartis AG strengths

IP Choke PointRegulated Standards Pipe

Segment mix

Alibaba Group Holding Limited segments

Full profile >

Taobao and Tmall Group

Oligopoly

41%

Alibaba International Digital Commerce Group

Competitive

12.1%

Cloud Intelligence Group (Alibaba Cloud)

Oligopoly

10.8%

Cainiao Smart Logistics Network Limited

Competitive

9.2%

Local Services Group

Oligopoly

6.1%

Digital Media and Entertainment Group

Competitive

All Others

Competitive

18.8%

Novartis AG segments

Full profile >

Cardiovascular, Renal and Metabolic

Oligopoly

17%

Immunology

Oligopoly

18.5%

Neuroscience

Oligopoly

9.4%

Oncology

Oligopoly

29.3%

Established Brands

Competitive

25.8%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.